Skip to main content
TipRanks
Go Ultimate75% OFF

Ibio (IBIO) AI Stock Analysis

2,329 Followers
IBIO

Ibio

(NASDAQ:IBIO)

Select Model
Rating:47Neutral
Price Target:$0.70▼(-7.09% Downside)
Action:reiterated
Date:11/17/26

The score is held down primarily by weak financial performance—large ongoing losses and material cash burn despite improving revenue—and a bearish technical setup with the stock trading below key moving averages and negative MACD. Offsetting factors include a stronger balance sheet (low leverage) and positive pipeline-related corporate updates, while valuation is hard to assess due to negative earnings and no dividend data.

Positive Factors
Pipeline DifferentiationThe extended primate results support a potentially differentiated obesity therapy focused on fat-selective weight loss and lean-mass preservation. If later studies reproduce these effects, IBIO-610 could address an important limitation of existing treatments and strengthen iBio’s strategic position.
Negative Factors
Persistent Large LossesThe company has not yet demonstrated a sustainable profit model, and its losses remain extremely large relative to revenue. Persistent negative earnings can erode equity over time, constrain strategic flexibility, and increase dependence on external financing while products remain under development.

Ibio (IBIO) vs. SPDR S&P 500 ETF (SPY)

-50%0%50%100%150%200%250%IBIO-24.82%SPY+11.73%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$52.71M
Dividend Yield
―
Average Volume (3M)
639.54K
Price to Earnings (P/E)
-2.6
Beta (1Y)
1.11
Revenue Growth
115.00%
EPS Growth
71.61%
Country
US
Employees
23
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Ibio Business Overview & Revenue Model

Company Description

iBio, Inc., a United States-based biotechnology firm, delivers contract development and manufacturing (CDMO) services to its collaborators and external clients. Its operations are structured into two distinct segments: Biopharmaceuticals and Bioproce...

Ibio Financial Statement Overview

Summary

Mixed fundamentals skew negative. Revenue has rebounded in the TTM period off a very small base, and the balance sheet is a relative strength with low leverage (TTM debt-to-equity ~0.03). However, profitability and cash generation remain very weak with large, persistent losses (TTM net income about -$34.9M) and ongoing cash burn (TTM operating cash flow about -$26.9M; FCF about -$27.6M).

Income Statement

18Very Negative

Balance Sheet

62Positive

Cash Flow

24Negative
Financial statement breakdown
BreakdownTTMJun 2026Jun 2025Jun 2024Jun 2023Jun 2022
Income Statement
Total Revenue1.07M100.00K400.00K225.00K01.88M
Gross Profit584.00K100.00K400.00K225.00K0-1.91M
EBITDA-34.07M-31.96M-17.04M-14.02M-27.85M-25.72M
Net Income-34.88M-33.04M-18.38M-24.91M-65.01M-50.39M
Balance Sheet
Total Assets88.65M99.11M23.18M28.73M41.21M99.41M
Cash, Cash Equivalents and Short-Term Investments76.65M88.04M8.58M14.21M7.33M33.52M
Total Debt2.07M2.20M3.51M4.46M17.07M25.77M
Total Liabilities10.08M13.40M8.30M7.41M25.83M35.92M
Stockholders Equity78.57M85.71M14.88M21.32M15.38M63.48M
Cash Flow
Free Cash Flow-27.59M-23.80M-15.32M-18.76M-36.17M-44.81M
Operating Cash Flow-26.94M-23.22M-15.30M-18.55M-30.44M-37.48M
Investing Cash Flow-10.96M-32.00M742.00K906.00K7.01M-5.13M
Financing Cash Flow55.22M103.05M8.93M24.49M2.30M-6.13M

Ibio Technical Analysis

Technical Analysis SentimentNegative
Last Price0.75

Price Trends

50DMA0.96Negative
100DMA1.20Negative
200DMA1.61Negative

Market Momentum

MACD-0.05Negative
RSI41.97Neutral
STOCH28.88Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IBIO, the sentiment is Negative. The current price of 0.75 is below the 20-day moving average (MA) of 0.77, below the 50-day MA of 0.96, and below the 200-day MA of 1.61, indicating a bearish trend. The MACD of -0.05 indicates Negative momentum. The RSI at 41.97 is Neutral, neither overbought nor oversold. The STOCH value of 28.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IBIO.

Ibio Risk Analysis

Ibio disclosed 62 risk factors in its most recent earnings report. Ibio reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

3 New Risks
1.Conducting clinical trials in Australia exposes us to additional regulatory, operational and legal risks that could delay development of our product candidates and increase our costs.Q2, 2026
2.Our Phase 1 clinical trial of IBIO-600 is subject to significant risks that could delay or prevent further development of this product candidate.Q2, 2026
3.Delays or difficulty in the enrollment of patients in any or all of our clinical trials could increase our development costs and delay completion of our clinical trials and associated regulatory submissions.Q2, 2026

Ibio Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

IBIO against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
IBIOIBIO47Neutral$52.71M-2.63-46.75%―115.00%71.61%
PULMPULM44Neutral$5.00M-1.15-154.64%―-100.00%29.48%
NERVNERV41Neutral$107.64M-0.08167.68%――-1306.84%
FBLGFBLG37Underperform$8.10M-0.25-431.79%――65.30%
CMMBCMMB32Underperform$11.88M-1.63-70.81%――56.99%

* Healthcare Sector Average

Performance Comparison

0%100%IBIONERVPULMCMMBASBPFBLGDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IBIO and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IBIOIbio Inc0.75-0.34-31.38%
NERVMinerva Neurosciences2.16-2.14-49.77%
PULMPulmatrix1.37-3.01-68.72%
CMMBChemomab Therapeutics Ltd.1.64-1.06-39.26%
ASBPAspire Biopharma Holdings, Inc.8.30-110.74-93.03%
FBLGFibroBiologics, Inc.0.90-5.99-86.94%

Ibio Corporate Events

Product-Related Announcements

iBio Reports Positive Preclinical Data for IBIO-610

Positive
Nov 17, 2026

On November 16, 2026, iBio reported extended preclinical data for IBIO-610, its long-acting Activin E-targeting antibody, from an obese non-human primate study. At week 28, body weight was 2.3% lower relative to vehicle; at week 24, total body fat, a...

Business Operations and StrategyExecutive/Board ChangesShareholder Meetings

iBio Shareholders Approve Governance and Capital Structure Changes

Positive
Oct 19, 2026

iBio, Inc. is a biotechnology company focused on developing therapeutics and vaccines using its proprietary technology platforms. The company operates in the life sciences industry and relies on equity-based incentive plans and access to capital mark...

Business Operations and StrategyProduct-Related Announcements

iBio Highlights IBIO-610 Obesity Antibody Preclinical Results

Positive
Oct 13, 2026

On Oct. 13, 2026, iBio reported preclinical body-composition data from an eight-week obese non-human primate study of IBIO-610, a potentially first-in-class Activin E antibody, tested alone and with the GLP-1 agonist semaglutide used for obesity. The...

Business Operations and StrategyProduct-Related Announcements

iBio Highlights Breakthrough Antibody Strategy for Obesity

Positive
Sep 14, 2026

In September 2026, iBio updated its corporate presentation to highlight a strategic focus on “breakthrough antibodies” for obesity and cardiometabolic diseases, positioning itself as a next-generation player beyond first-wave GLP-1 incretin therapies...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 17, 2026